PharmaShots | Incisive News in 3 Shots

Subscribe Now

Innovent

Innovent’s Sintbilo (tafolecimab) Receives the NMPA’s Approval for Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

Innovent’s Sintbilo (tafolecimab) Receives the NMPA’s Approval for Adult Patients with Primary Hypercholesterolemia and Mixed Dysl...

August 17, 2023

Innovent and Eli Lilly Report Real-World Analysis of Sintilimab and Bevacizumab Biosimilar for Hepatocellular Carcinoma

Innovent and Eli Lilly Report Real-World Analysis of Sintilimab and Bevacizumab Biosimilar for Hepatocellular Carcinoma

August 8, 2023

$Innovent and IASO Bio Receive the NMPA’s Approval of Fucaso (equecabtagene autoleucel) for the Treatment of Relapsed or Refractory Multiple Myeloma$

Innovent and IASO Bio Receive the NMPA’s Approval of Fucaso (equecabtagene autoleucel) for the Treatment of Relapsed or Refractory...

July 3, 2023

Innovent Presents P-I Clinical Trial Results of IBI322 for the Treatment of Classic Hodgkin Lymphoma at EHA 2023

Innovent Presents P-I Clinical Trial Results of IBI322 for the Treatment of Classic Hodgkin Lymphoma at EHA 2023

June 13, 2023

Innovent’s Olverembatinib Receives the NMPA’s Breakthrough Therapy Designation for Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor

Innovent’s Olverembatinib Receives the NMPA’s Breakthrough Therapy Designation for Succinate Dehydrogenase-Deficient Gastrointesti...

June 6, 2023

Innovent Entered into Clinical Trial Collaboration and Supply Agreement with Merck KGaA to Evaluate IBI351 + Erbitux (cetuximab) for KRASG12C-Mutated NSCLC in China

Innovent Entered into Clinical Trial Collaboration and Supply Agreement with Merck KGaA to Evaluate IBI351 + Erbitux (cetuximab) f...

June 2, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us